Amphastar Pharmaceuticals (AMPH) Operating Margin: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.37-0.06 (-0.24%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

AMPH Operating Margin Metrics

OPERATING MARGIN

15.66%

OPERATING MARGIN AVG TTM

17.28%

OPERATING MARGIN AVG 3Y

25.73%

OPERATING MARGIN AVG 5Y

22.79%

OPERATING MARGIN AVG 10Y

12.21%

OPERATING MARGIN AVG 15Y

N/A

OPERATING MARGIN AVG 20Y

N/A

CURRENT VS TTM AVG

-9.37%

CURRENT VS 3Y AVG

-39.15%

CURRENT VS 5Y AVG

-31.29%

CURRENT VS 10Y AVG

+28.25%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.00%

median of 384 covered companies

CURRENT VS SECTOR MEDIAN

N/A

vs the sector median at left

NAME	MARKET CAP	OPERATING MARGIN	TTM	3Y	5Y
Amphastar Pharmaceuticals, Inc. (AMPH)	$1.12B	15.66%	17.28%	25.73%	22.79%
Castle Biosciences, Inc. (CSTL)vs ›	$1.12B	-8.99%	-4.92%	-23.48%	-24.49%
Bicara Therapeutics Inc. Common Stock (BCAX)vs ›	$1.14B	0.00%	0.00%	0.00%	0.00%
GoodRx Holdings, Inc. (GDRX)vs ›	$1.16B	10.25%	9.64%	3.98%	-5.39%
Teladoc Health, Inc. (TDOC)vs ›	$1.05B	-6.98%	-25.06%	-156.73%	-114.38%
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.20B	0.00%	0.00%	0.00%	0.00%
Cronos Group Inc. (CRON)vs ›	$1.21B	-11.96%	-38.52%	-75.67%	-204.09%
Damora Therapeutics, Inc. (DMRA)vs ›	$1.24B	0.00%	0.00%	0.00%	0.00%
Aktis Oncology, Inc. (AKTS)vs ›	$989.05M	-1149.52%	-2324.93%	-1162.47%	-1162.47%
Cullinan Therapeutics, Inc. (CGEM)vs ›	$985.79M	0.00%	0.00%	0.00%	-59.79%

NAME

MARKET CAP

OPERATING MARGIN

TTM

Amphastar Pharmaceuticals, Inc. (AMPH)

$1.12B

15.66%

17.28%

25.73%

22.79%

Castle Biosciences, Inc. (CSTL)vs ›

$1.12B

-8.99%

-4.92%

-23.48%

-24.49%

Bicara Therapeutics Inc. Common Stock (BCAX)vs ›

$1.14B

0.00%

GoodRx Holdings, Inc. (GDRX)vs ›

$1.16B

10.25%

9.64%

3.98%

-5.39%

Teladoc Health, Inc. (TDOC)vs ›

$1.05B

-6.98%

-25.06%

-156.73%

-114.38%

Avalyn Pharma Inc. Common Stock (AVLN)vs ›

$1.20B

0.00%

Cronos Group Inc. (CRON)vs ›

$1.21B

-11.96%

-38.52%

-75.67%

-204.09%

Damora Therapeutics, Inc. (DMRA)vs ›

$1.24B

0.00%

Aktis Oncology, Inc. (AKTS)vs ›

$989.05M

-1149.52%

-2324.93%

-1162.47%

Cullinan Therapeutics, Inc. (CGEM)vs ›

$985.79M

0.00%

-59.79%

Operating Margin FAQ

What is the operating margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The operating margin for AMPH stock is 15.66%.

Is Amphastar Pharmaceuticals, Inc.'s operating margin high or low?

The operating margin of 15.66% is 31% below its 5-year average of 22.79%, near the low end of its 5-year range (7.96%–40.25%).

What is the TTM average operating margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The TTM average operating margin for AMPH stock is 17.28%.

What is the 3Y average operating margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 3Y average operating margin for AMPH stock is 25.73%.

What is the 5Y average operating margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 5Y average operating margin for AMPH stock is 22.79%.

What is the 10Y average operating margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 10Y average operating margin for AMPH stock is 12.21%.

DATE	OPERATING MARGIN
2026-06-30	21.60%
2026-03-31	7.96%
2025-12-31	19.45%
2025-09-30	13.20%
2025-06-30	24.19%
2025-03-31	21.87%
2024-12-31	24.20%
2024-09-30	30.21%
2024-06-30	30.27%
2024-03-31	27.94%
2023-12-31	30.31%
2023-09-30	40.25%
2023-06-30	25.32%
2023-03-31	23.88%
2022-12-31	28.02%
2022-09-30	19.34%
2022-06-30	20.10%
2022-03-31	17.96%
2021-12-31	20.06%
2021-09-30	22.08%
2021-06-30	10.39%
2021-03-31	10.00%
2020-12-31	3.00%
2020-09-30	4.22%
2020-06-30	-3.41%
2020-03-31	8.83%
2019-12-31	-0.29%
2019-09-30	3.00%
2019-06-30	1.23%
2019-03-31	-3.98%
2018-12-31	1.72%
2018-09-30	3.38%
2018-06-30	-4.02%
2018-03-31	-16.98%
2017-12-31	-2.75%
2017-09-30	-4.87%
2017-06-30	3.35%
2017-03-31	2.48%
2016-12-31	-7.10%
2016-09-30	9.03%
2016-06-30	15.18%
2016-03-31	6.86%
2015-12-31	18.68%
2015-09-30	-5.87%
2015-06-30	-19.05%
2015-03-31	-12.76%
2014-12-31	-12.57%
2014-09-30	-13.09%
2014-06-30	-2.39%
2014-03-31	-4.29%
2013-12-31	5.34%
2013-09-30	0.38%
2013-06-30	19.16%
2013-03-31	4.44%
2012-12-31	12.82%

DATE

OPERATING MARGIN

2026-06-30

21.60%

2026-03-31

7.96%

2025-12-31

19.45%

2025-09-30

13.20%

2025-06-30

24.19%

2025-03-31

21.87%

2024-12-31

24.20%

2024-09-30

30.21%

2024-06-30

30.27%

2024-03-31

27.94%

2023-12-31

30.31%

2023-09-30

40.25%

2023-06-30

25.32%

2023-03-31

23.88%

2022-12-31

28.02%

2022-09-30

19.34%

2022-06-30

20.10%

2022-03-31

17.96%

2021-12-31

20.06%

2021-09-30

22.08%

2021-06-30

10.39%

2021-03-31

10.00%

2020-12-31

3.00%

2020-09-30

4.22%

2020-06-30

-3.41%

2020-03-31

8.83%

2019-12-31

-0.29%

2019-09-30

3.00%

2019-06-30

1.23%

2019-03-31

-3.98%

2018-12-31

1.72%

2018-09-30

3.38%

2018-06-30

-4.02%

2018-03-31

-16.98%

2017-12-31

-2.75%

2017-09-30

-4.87%

2017-06-30

3.35%

2017-03-31

2.48%

2016-12-31

-7.10%

2016-09-30

9.03%

2016-06-30

15.18%

2016-03-31

6.86%

2015-12-31

18.68%

2015-09-30

-5.87%

2015-06-30

-19.05%

2015-03-31

-12.76%

2014-12-31

-12.57%

2014-09-30

-13.09%

2014-06-30

-2.39%

2014-03-31

-4.29%

2013-12-31

5.34%

2013-09-30

0.38%

2013-06-30

19.16%

2013-03-31

4.44%

2012-12-31

12.82%

Operating Margin: 15.66%

AMPH Operating Margin

AMPH Average Operating Margin Chart

AMPH Current vs Average Operating Margin Chart

AMPH Operating Margin Metrics

AMPH Competitors' Operating Margin

Operating Efficiency

Operating Margin Formula & Definition

Operating Margin FAQ

AMPH Operating Margin History

Related Metrics